Susquehanna Fundamental Investments LLC Invests $690,000 in Olema Pharmaceuticals, Inc. $OLMA

Susquehanna Fundamental Investments LLC acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 55,121 shares of the company’s stock, valued at approximately $690,000. Susquehanna Fundamental Investments LLC owned about 0.06% of Olema Pharmaceuticals at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of OLMA. Bain Capital Life Sciences Investors LLC increased its position in shares of Olema Pharmaceuticals by 24.3% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after acquiring an additional 1,664,687 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Olema Pharmaceuticals by 11.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after purchasing an additional 750,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Olema Pharmaceuticals by 5.9% in the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock valued at $106,013,000 after buying an additional 398,294 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of Olema Pharmaceuticals in the 2nd quarter valued at $88,803,000. Finally, BlackRock Inc. purchased a new stake in shares of Olema Pharmaceuticals in the 2nd quarter valued at $84,001,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

OLMA has been the subject of a number of research analyst reports. Citigroup lowered their target price on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Guggenheim lowered their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen cut shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. HC Wainwright cut their target price on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings lowered shares of Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Olema Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.40.

Olema Pharmaceuticals Stock Up 2.6%

OLMA stock opened at $10.83 on Thursday. The company’s 50 day moving average price is $11.45 and its 200 day moving average price is $14.02. The firm has a market capitalization of $947.62 million, a price-to-earnings ratio of -5.11 and a beta of 1.98. Olema Pharmaceuticals, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.86 and a current ratio of 8.86.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). On average, equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.43 EPS for the current fiscal year.

Insider Activity

In other news, Director Cyrus Harmon sold 12,500 shares of Olema Pharmaceuticals stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares of the company’s stock, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.56% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.